Save $50 on 1 treatment of Dysport! Expires Dec 31, 2010

Save up to $450 on your favorite fillers! Expires Dec 31, 2010

NEW STUDY DATA PRESENTED AT THE AMERICAN ACADEMY OF FACIAL PLASTIC AND RECONSTRUCTIVE SURGERY 2010 ANNUAL FALL MEETING REVEAL
DYSPORT™ SUPERIORITY VERSUS BOTOX® COSMETIC

Clinical Results Show Efficacy Benefit with Dysport™ for Treatment of Crow’s Feet

ALEXANDRIA, VA (SEPTEMBER 24, 2010)

At the American Academy of Facial Plastic and Reconstructive Surgery annual meeting, clinical results were presented demonstrating a significant efficacy advantage with Dysport™ (abobotulinumtoxinA) over Botox^® Cosmetic (onabotulinumtoxinA) for the treatment of Crow’s feet.  The data were presented Friday, September 24 at a scientific session at the AAFPRS 2010 Annual Fall Meeting, taking place September 23-26 in Boston.The 90-subject study, titled “Internally Controlled Double-Blind Comparison of Onabotulinum and Abobotulinum Toxin Type A (Nettar, Kartik D., M.D., et. al),” met its primary endpoint (p=0.01) of greater efficacy of action with Dysport™ as defined by investigator assessment of maximum contraction at Day 30 post injection compared to Day 0.  Additionally, a secondary endpoint—subject assessment at maximum contraction at Day 30 compared to Day 0—also demonstrated statistical significance with Dysport™ (p=0.027).

“Botox has long been considered the gold standard of injectables, so this data showing Dysport’s stronger efficacy is compelling,” said Corey S. Maas, M.D., F.A.C.S., AAFPRS Group Vice President for Public and Regulatory Affairs.  “Since injectables are the non-surgical cosmetic procedure rising fastest in popularity, it is important to continue honing new applications for existing treatments.  Dysport’s potential here is exciting as Crow’s feet are a common concern for many men and women.”

READ MORE…